2-FEA
N-ethyl-2-fluoroamphetamine
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2-FEA (2-fluoroethamphetamine) is a synthetic stimulant of the substituted amphetamine class. It is the N-ethyl homolog of 2-fluoroamphetamine, sitting between the austere profile of 2-FMA and the warmer character of 3-FEA. It floods the brain with dopamine and norepinephrine, producing the stimulant euphoria and arousal common to the amphetamine family.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, methamphetamine, 2-FA +2 moreamphetamine, methamphetamine, 2-FA, 2-FMA, other dopamine-releasing stimulants show less
2-FEA appeared on European research chemical markets around 2015, part of a wave of fluorinated amphetamine analogs.[2] Its positional isomer 3-FEA was analytically confirmed from seized material in 2018,[3] establishing the class's real-world market presence. It remains unscheduled by name in most jurisdictions, controlled only through blanket NPS and analogue laws in places like the UK[4] and Germany.
Subjective effects include cognitive euphoria, increased focus, wakefulness, and mild empathogenic warmth.[5] The experience is a compressed stimulant arc with a subtle serotonin-driven warmth — more sociable than 2-FMA, but nothing like the emotional depth of 3-FEA. Compulsive redosing, anxiety at higher doses, and low mood in the hours after use are the most characteristic unwanted effects.
2-FEA carries moderate dependence risk and meaningful cardiovascular toxicity.[6][7] Blood pressure elevation is the primary acute danger: related fluorinated amphetamines have caused heart attacks and brain hemorrhage,[8] and combining 2-FEA with serotonin-affecting drugs risks a life-threatening overheating response. No pharmacological study of 2-FEA has been published; everything known comes from structural analogy and user reports.
History[edit]
Discovery and synthesis
No publication records the first synthesis of 2-FEA. It belongs to the fluorinated amphetamine family that emerged from halogen-substitution programs in mid-20th century medicinal chemistry.[9] Its first appearance was on the commercial research chemical market, not in a laboratory publication.
Market emergence
Online discussions place 2-FEA's availability from Swedish research chemical vendors at approximately 2015.[2] Its positional isomer 3-FEA was analytically confirmed from seized material in 2018,[3] showing the class had reached sufficient market penetration to attract forensic attention. The hydrochloride salt is now sold as an analytical reference standard.[10]
Prohibition and modern status
Germany controlled 2-FEA under its new psychoactive substances law in November 2016. The United Kingdom's Psychoactive Substances Act 2016 brought it under prohibition alongside all non-exempted psychoactives.[4] No jurisdiction has specifically scheduled 2-FEA by name — controls rely on structural analog provisions or blanket NPS legislation.
The name follows the convention used across fluorinated amphetamine research chemicals: the numeral indicates ring position (2- for ortho), F for fluorine, EA for ethamphetamine. Community discussions sometimes describe 2-FEA as a "diet 4-FA" — referencing the more prominent entactogenic fluoroamphetamine — though the pharmacological comparison is imprecise given their different fluorine positions and N-alkyl substitutions.
Chemistry[edit]
Structural class
2-FEA belongs to the substituted amphetamine family. It carries the standard amphetamine backbone modified by a fluorine atom at the ortho (2-) position of the phenyl ring and an ethyl group on the nitrogen. It is the N-ethyl homolog of 2-fluoroamphetamine (2-FA) and the ortho-positional isomer of 3-FEA.
Molecular properties
Its molecular formula is C₁₁H₁₆FN, with a molecular weight of 181.25 g/mol as the freebase and approximately 217.7 g/mol as the hydrochloride salt.[10] Chiral separation methods applicable to fluorinated amphetamine analogs have been documented,[11][12] though no published work has applied them to 2-FEA specifically.
Pharmacology[edit]
Mechanism of action
No direct binding or release data have been published for 2-FEA. 2-FEA is presumed to act as a monoamine releasing agent — entering the dopamine and norepinephrine transporters and reversing their direction, flooding the synapse with both neurotransmitters.[1] This mechanism drives stimulant euphoria and arousal.
N-ethylation — having an ethyl rather than methyl group on the nitrogen — increases relative activity at the SERT compared to purely catecholaminergic analogs.[13] Users describe a warmth exceeding purely catecholaminergic stimulants,[2] consistent with some serotonin release — though the degree remains unquantified.[5]
Pharmacokinetics
No human pharmacokinetic data exist for 2-FEA. By analogy to 2-FMA,[9] the primary metabolic pathway is likely N-deethylation to 2-fluoroamphetamine (2-FA), with possible additional hydroxylation. The insufflated duration of 1–2.5 hours is notably short for an amphetamine — the reason is unknown.citation needed
Neuroscience[edit]
Where it acts
2-FEA primarily releases dopamine and norepinephrine in the brain's reward and arousal circuits.[1] Dopamine flooding the nucleus accumbens drives euphoria and motivated wanting. Norepinephrine released from the locus coeruleus produces the wakefulness and heightened alertness of the stimulant state.
If 2-FEA produces meaningful serotonin release — predicted by its N-ethyl structure[13] — this would modulate emotional processing in the amygdala and prefrontal cortex, explaining the mild empathogenic warmth users describe.
Why it matters
The ratio of dopamine to serotonin release determines whether a monoamine releaser produces compulsive stimulant wanting or softer emotional warmth.[6] Fluorinated amphetamines including 4-FA elevate both drug liking and wanting in humans,[14] consistent with significant abuse potential. The cardiovascular effects reflect peripheral norepinephrine release; severe overheating reflects disruption of the brain's temperature regulation.[15]
The most pressing unknown is 2-FEA's actual dopamine-to-serotonin selectivity ratio — the measurement that would resolve whether it is pharmacologically a stimulant, entactogen, or hybrid. Whether ortho-fluorination produces the same serotonergic augmentation as para-fluorination remains untested.[16] The unusually short insufflated duration is also unexplained. Para-halogenation increases mitochondrial toxicity in neuronal cells;[17] whether this extends to ortho-fluorination has not been investigated.
Subjective Effects[edit]
The 2-FEA experience occupies a narrow space between functional stimulant and mild entactogen. Insufflated, it delivers a rapid, clean arc of cognitive stimulation and physical energy, with a serotonin-driven warmth that adds quiet sociability. The window is short, and the experience resolves cleanly without a heavy tail.
Among fluorinated amphetamines, 2-FEA sits between the austere functionality of 2-FMA and the warmer character of 3-FEA. Users familiar with dextroamphetamine will recognize the core profile — elevated mood, task engagement, physical energy — with an added empathogenic hint reminiscent of a muted 4-FA.
Effect Grid
At common doses (30–40 mg insufflated), the core stimulant experience fully manifests. Cognitive euphoria, enhanced focus, motivation enhancement, thought acceleration, and pronounced wakefulness dominate the cognitive profile. A subtle entactogenic warmth — sociability enhancement and mild empathic quality — is reported by some users, though less pronounced than in 3-FEA.
Physical stimulation is prominent: increased energy, appetite suppression, dry mouth, and increased heart rate. Bruxism may emerge. Pupil dilation is typical. Temperature dysregulation and mild vasoconstriction are possible.
The total insufflated duration is 1–2.5 hours, with aftereffects lasting 1–3 hours. Compulsive redosing urge begins at this tier — the short duration makes repeated dosing tempting, but each redose adds cumulative cardiovascular strain.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Brightness alteration · Auditory hallucinations · External hallucinations · Shadow people
Pupil dilation · Dry mouth · Respiratory stimulation · Excessive sweating · Insomnia · Dehydration sensation · Restlessness · Body high · Heart rate perception changes · Muscle tension · Nasal congestion · Physical fatigue · Temperature dysregulation · Bruxism · Headache · Nausea · Sexual arousal enhancement · Tingling / electric sensations · Watery eyes · Motor control enhancement · Tactile euphoria · Increased urination · Sexual arousal suppression · Constipation · Dizziness · Motor control impairment · Trembling · Tactile hallucination
Excessive sweating · Insomnia · Dehydration sensation · Restlessness · Body high · Heart rate perception changes · Muscle tension · Nasal congestion · Physical fatigue · Bruxism · Headache · Nausea · Sexual arousal enhancement · Tingling / electric sensations · Watery eyes · Motor control enhancement · Tactile euphoria · Increased urination · Sexual arousal suppression · Constipation · Dizziness · Motor control impairment · Trembling · Tactile hallucination
Motivation enhancement · Information processing enhancement · Cognitive fatigue · Cognitive flexibility · Analysis enhancement · Thought organization · Motivation suppression · Aesthetic enhancement · Language enhancement · Memory enhancement · Novelty enhancement · Pattern recognition enhancement · Thought deceleration
Analysis enhancement · Thought organization · Motivation suppression · Aesthetic enhancement · Language enhancement · Memory enhancement · Novelty enhancement · Pattern recognition enhancement · Thought deceleration
Anhedonia · Dysphoria · Emotional lability · Emotional suppression · Mania
Emotional suppression
Flow state · Sociability enhancement · Depersonalization · Derealization
Timeline
Initial awareness of stimulation emerges as the compound absorbs through nasal mucosa. Slight alertness increase and mild nasal discomfort.
Rapid escalation of stimulant effects — mood lift, physical energy, and focus sharpening build noticeably over minutes.
Full expression of stimulant and mild entactogenic effects — cognitive euphoria, motivation enhancement, wakefulness, and sociability at maximum intensity. Cardiovascular effects (heart rate, blood pressure) are most pronounced.
Gradual decline in stimulation and euphoria. Residual alertness and focus persist but diminish steadily. Appetite begins to return.
Residual wakefulness and possible restlessness as catecholamine levels normalize. Mild fatigue, irritability, and low mood are common. Insomnia may persist for several hours.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · 2-FA
Toxicity
No lethal dose has been established for 2-FEA, and no published overdose reports or deaths specific to 2-FEA have been identified.safety citation needed All toxicity assessment is inferred from structurally related fluorinated amphetamines.
Heart and circulation
Cardiovascular toxicity is the primary acute danger. The related compound 4-fluoroamphetamine produces blood pressure spikes exceeding those of both MDMA and amphetamine, with documented cases of heart muscle damage, heart attack, and brain hemorrhage.[8] In the only controlled human trial of a fluoroamphetamine, a 150 mg study arm was cancelled after safety review due to severe blood pressure elevation at the 100 mg dose.[18]
Amphetamine-type stimulants broadly cause high blood pressure, accelerated artery hardening, and weakened heart muscle through excessive stress-hormone release.[7]
Overheating
Stimulant-induced overheating can progress to brain swelling and death, worsened by warm environments and physical exertion.[15] Amphetamine-like new psychoactive substances share this overheating risk with MDMA-type stimulants.[19]
Neurotoxicity
Para-halogenation of amphetamine increases cell death in neuronal models compared to non-halogenated analogs.[17] Whether this applies to the ortho-fluorination in 2-FEA has not been investigated.
Overdose presentation
Based on amphetamine-type stimulant overdose patterns,[20] expected signs include dilated pupils, tremor, agitation, confusion, hallucinations, paranoia, seizures, and combative behavior. Benzodiazepines are first-line treatment for agitation and seizures.
Psychological risks
Anxiety, paranoia, and stimulant psychosis — paranoid thinking and hallucinations driven by dopamine overload — are documented risks with high-dose or chronic amphetamine use. Community reports note anxiety and paranoia at higher doses or after extended redosing sessions.[5]
Compulsive redosing increases exposure to cardiovascular and psychological harm. Post-use depression and irritability reflect dopamine and norepinephrine depletion following stimulant use.
Tolerance and dependence
Tolerance to 2-FEA's effects develops with repeated use. Community databases report a tolerance half-life of approximately 5 days and full reset within 1.5 weeks.safety citation needed Cross-tolerance with other dopamine-releasing stimulants — including amphetamine and related fluoroamphetamines — is expected.
Dependence liability is moderate for both physical and psychological dimensions. Fluorinated amphetamines produce drug liking and wanting comparable to classical stimulants,[14] 2-FA shows full methamphetamine-like abuse potential in animal studies,[21] and catecholaminergic releasers carry higher abuse liability than serotonin-selective agents.[6][1] Withdrawal produces fatigue, depressed mood, appetite enhancement, and anhedonia.
Drug interactions
No 2-FEA-specific interaction studies have been conducted. All assessments reflect class-level pharmacology.
Serotonergic combinations are the most dangerous class. Tramadol combined with a monoamine releaser can trigger overheating, muscle rigidity, seizures, and death,[22] compounded by potential metabolic interaction.[23]
MDMA co-administration produces additive monoamine excess through competing reverse-transport, creating synergistic risk for overheating and cardiovascular collapse.[24] MDMA also inhibits the enzyme that breaks down 2-FEA, slowing its clearance.[25] Fatal serotonin syndrome from MDMA combined with monoamine oxidase-modulating drugs is documented.[26]
Monoamine oxidase inhibitors (MAOIs) combined with any monoamine releasing agent risk life-threatening blood pressure crisis and overheating. Amphetamine derivatives themselves have some MAO-inhibiting activity,[27] compounding the risk further.
Stimulant-stimulant combinations — particularly cocaine — create unsustainable dopamine and norepinephrine levels: cocaine blocks the transporters while 2-FEA reverses them.[19] The cardiovascular strain carries risk of fatal heart rhythm disturbance or heart attack.
SSRIs and SNRIs add serotonin load, increasing the risk of overheating.[28]
Alcohol may increase amphetamine blood levels, blunt the sense of intoxication, and add cardiovascular strain.
Contraindications
No substance-specific contraindication data exist for 2-FEA. The following are inferred from amphetamine class pharmacology.inferred
Heart conditions — high blood pressure, coronary artery disease, weakened heart muscle, irregular heartbeat, or history of stroke — are absolute contraindications. Catecholamine-releasing stimulants significantly elevate risk of heart attack, stroke, and cardiac arrest.[7]
Concurrent MAOI therapy is an absolute contraindication due to risk of life-threatening blood pressure crisis and overheating.[27]
Concurrent serotonergic medication (SSRIs, SNRIs, tramadol, other serotonin-active drugs) is a strong contraindication due to additive serotonin toxicity risk.[28]
Seizure disorders are a relative contraindication; amphetamine-type stimulants can lower seizure threshold.
Overactive thyroid is a relative contraindication due to additive stimulant cardiovascular effects.
Psychiatric conditions — particularly psychotic disorders, severe anxiety, and bipolar disorder — are relative contraindications; stimulants can trigger psychotic episodes, panic attacks, and manic states.
Pregnancy and breastfeeding are absolute contraindications; amphetamine-type stimulants are associated with low birth weight, preterm delivery, and withdrawal symptoms in newborns.safety citation needed
Harm Reduction[edit]
Forms & Identification
2-FEA is a white crystalline powder indistinguishable by appearance from dozens of other research chemical stimulants, including its own positional isomers 3-FEA and 4-FEA. Standard reagent testing confirms the presence of an amphetamine-type substance but cannot identify specific fluorinated analogs or differentiate between isomers.
For a substance with no established safety profile, every batch carries uncertainty about what is actually being consumed. Analytical services using GC-MS or equivalent techniques are the most reliable way to verify identity.
Guidelines
- Use a milligram-precision scale for every dose — volumetric estimation of powder is unreliable
- Start with a low dose from any new batch, as purity varies between vendors and lots
- Plan the session duration before beginning — the short insufflated timeline makes repeated dosing tempting
- Keep water accessible and maintain hydration without overdrinking
- Avoid use in hot environments or during intense physical activity to reduce overheating risk
- Allow a minimum of 1.5–2 weeks between sessions to permit tolerance reset
- Do not use alone for the first time with any new batch
Set & Setting
The short duration of insufflated 2-FEA creates a particular risk pattern: the compressed timeline invites redosing before the previous dose has cleared. Choosing a setting where redosing pressure is low — away from large supplies, with a planned activity duration matching a single dose — reduces this risk.
The mild empathogenic quality is more apparent in social settings; cognitive effects are more salient during solo focus tasks.
Aftercare & integration. The stimulant comedown from 2-FEA reflects temporary depletion of dopamine and norepinephrine. Post-use fatigue, low mood, and irritability are expected and typically resolve within 24–48 hours.
Prioritize sleep — stimulant use disrupts sleep architecture, and recovery sleep is the most effective intervention for comedown symptoms. Eat a full meal even if appetite is suppressed; depletion responds to adequate nutrition and rest. Avoid caffeine and other stimulants during the recovery window, as they prolong the depletion state rather than alleviating it.
If low mood persists beyond 3–4 days or deepens into inability to function, speak with a healthcare provider. Repeated or worsening post-use depression can signal an escalating pattern of use.
Recovery & Support
Compulsive redosing is the most commonly reported pattern of problematic 2-FEA use. If sessions are becoming longer, doses are increasing, or time between sessions is shrinking, these are signs of developing dependence.
Amphetamine-type stimulant dependence responds to structured support. SMART Recovery and similar programs offer evidence-based frameworks for stimulant use disorders. Tracking use frequency and dose in a journal creates accountability and makes patterns visible. A healthcare provider experienced with substance use can assess whether pharmacological support is appropriate.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, irregular or pounding heartbeat, seizure, loss of consciousness, or a body temperature hot to the touch through clothing all indicate a medical emergency — not just an uncomfortable experience.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Keep the person calm and in a cool environment
- 3. Do not restrain unless there is immediate danger of self-harm
- 4. If unconscious but breathing, place in the recovery position
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (2-FEA or "a fluorinated amphetamine stimulant"), the estimated amount taken, the time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for amphetamine-type stimulant overdose. Hospital treatment centers on managing symptoms — benzodiazepines for agitation and seizures, cooling measures for overheating, and blood pressure management.
Legal Status[edit]
As of 2026, no jurisdiction has specifically scheduled 2-FEA by name. Controls in all jurisdictions rely on structural analog provisions, blanket NPS legislation, or structural similarity clauses. All legal status information should be verified against current government databases before reliance.citation needed
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Potentially Schedule II (Federal Analogue Act) | Not specifically scheduled. As a structural amphetamine analog, subject to Schedule II treatment under 21 U.S.C. § 813 if intended for human consumption. |
| United Kingdom | Illegal (production, supply, import, export) | Covered by the Psychoactive Substances Act 2016.[4] May additionally fall under Class A of the Misuse of Drugs Act 1971 via analogue provisions. |
| Germany | Controlled under NpSG | Neue-psychoaktive-Stoffe-Gesetz, effective 2016-11-26. Production, import for market placement, administration to others, and trading are punishable; personal possession is not penalized. |
| Netherlands | Uncertain | May be covered by NPS legislation. Previously available through research chemical vendors; current legal status unconfirmed.citation needed |
| Canada | Likely controlled | Controlled Drugs and Substances Act covers amphetamines and structural analogs. No substance-specific scheduling confirmed. |
| Australia | Likely Schedule 9 | TGA Poisons Standard Schedule 9 covers NPS analogs. No substance-specific scheduling confirmed. |
| Sweden | Likely controlled | Narcotics Act analogue provisions. Swedish vendors historically sold 2-FEA; regulatory response anticipated. |
references
- [1] ^abcdSimmler LD, Liechti ME (2018) Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_113
- [2]
- [3] ^abYanini Á, Armenta S, Esteve-Turrillas F, Galipienso N, de la Guardia M (2018) Identification and characterization of the new psychoactive substance 3-fluoroethamphetamine in seized material — Forensic Toxicology doi:10.1007/s11419-018-0416-y
- [4] ^abcAl-Banaa I, Hawkins L, Hill SL, et al. (2020) Effect of the UK Psychoactive Substances Act 2016 on episodes of toxicity related to new psychoactive substances as reported to the National Poisons Information Service — International Journal on Drug Policy doi:10.1016/j.drugpo.2020.102672
- [5]
- [6] ^abcRothman RB, Baumann MH (2006) Therapeutic potential of monoamine transporter substrates — Current Topics in Medicinal Chemistry PMID:17017961